WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

ANTIBIOTIC SUCEPTIBILITY OF EXTENDED SPECTRUM BETALACTIMASE [ESBL] PRODUCING ESCERICHIA COLI.

Abdulghani Mohamed Alsamarai*, Ibraheem Abdul-Rahman Latif and Mohamed Mohsen Abdul-Aziz

ABSTRACT

Background: ESBL E.coli producers prevalence increased worldwide and contributed to epidemiological changes in urinary tract infection pattern and interfere with management of urinary tract infection. Aim: to determine the frequency ESBL producing E. coli and clarify their susceptibility to antibiotics. Materials and Methods: Urine samples cultured on MacConkey and blood agar. Bacterial isolates identification, antibiotics susceptibility and ESBL were determined using VITEX 2 system. Results: All E. coli isolates were resistant to Ampicillin, Mezlocilin and Piperacillin, while all were sensitive to Ertapenem, Fosfomycin and Tigecycline. Although, this study shows that ESBL producing E. coli uropathogen isolates was high [61.5 %, 32/52], however, the rate was within the range reported globally. ESBL producing E. coli shows maximum resistance to Ampicillin, Cefazolin, Cefepime, Cefotaxime, Tetracycline, Mezlocilin, Piperacillin, Cefuroxime (100%) and ceftazidime (93.7%) while minimum resistance was to Ertapenem, Tigecycline, Fosfomycin (3.1%), Imipenem (6.2%) and Amikacin, Nitrofurantion (9.6%). ESBL producing E. coli was with higher rate of resistance as compared to ESBL negative E. coli. Conclusion: The high rate of ESBL E.coli producer’s isolates is a community and nosocomial health problem that associated with emergence of antimicrobial resistance which attributed to treatment failure of UTI and recurrent infections. High rate of resistance to common antimicrobial agents that form the first and second line of UTI treatment illustrate the importance of determination of ESBL production especially in cases with poor prognosis or with recurrent infections.

Keywords: Urinary tract infection, UTI, ESBL, E. coli, antibiotic susceptibility.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More